Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacira Pharmaceuticals reports record revenues and optimistic growth outlook

Pacira Pharmaceuticals had a strong financial performance in 2022, driven by EXPAREL's success and strategic initiatives. While facing challenges in pricing and reimbursement, the company is optimistic about future opportunities for growth through label expansions and market strategies.

Pacira Pharmaceuticals (PCRX) excels in Q1 2023 earnings call

Pacira Pharmaceuticals (PCRX) demonstrated robust financial performance, innovation in non-opioid pain management, and strategic market positioning in Q1 2023.
While facing challenges such as potential surgery trend moderation and pediatric market penetration, the company is leveraging opportunities in expanding EXPAREL use and regulatory advancements.
Overall, Pacira's focus on patient-centric solutions and market expansion initiatives position it well for continued growth and leadership in the pain management sector.

Pacira Pharmaceuticals reports strong Q2 performance and eyes growth

Pacira Pharmaceuticals delivered a strong Q2 performance with robust revenues, led by EXPAREL sales and improved gross margins, showcasing financial stability and growth potential.
While facing challenges in market adoption and regulatory hurdles, the company's strategic strengths in non-opioid pain management and product diversification present opportunities for long-term growth.
Anticipated initiatives like the NOPAIN Act and the launch of a lower extremity nerve block offer significant growth prospects, positioning Pacira Pharmaceuticals for continued success in the market.
Overall, Pacira Pharmaceuticals' focus on innovation, market access, and operational efficiency underscores its commitment to sustainable growth and leadership in non-opioid pain management.

Pacira Pharmaceuticals adjusts EXPAREL sales guidance amidst growth opportunities

Pacira Pharmaceuticals (PCRX) navigated market challenges by adjusting EXPAREL sales guidance while maintaining financial targets. Strong performance in EXPAREL and other product lines, coupled with strategic investments and partnerships, position the company for future growth. Addressing competitive threats and seizing expansion opportunities are key focus areas for sustained success.

Pacira Pharmaceuticals reports robust Q4 performance and strategic growth plans

Pacira Pharmaceuticals (PCRX) showcases strong financial performance and strategic focus on non-opioid pain management.
Challenges include patent defense against eVenus and organizational restructuring for sustainable growth.
Opportunities lie in EXPAREL's growth trajectory, NOPAIN legislation, and expanding therapeutic strategies.
Overall, Pacira Pharmaceuticals is poised for continued success amid the opioid crisis, with a clear vision for future growth.

Pacira Pharmaceuticals sees growth potential with EXPAREL and gene therapy

Pacira Pharmaceuticals reports strong sales performance for EXPAREL and other products, despite margin impacts.
The company is focused on growth and penetration in the marketplace, leveraging new indications and partnerships.
PCRX-201 shows promise for future growth opportunities, supported by FDA's RMAT designation.
Analyst questions and challenges like maintaining margins and capital allocation decisions are areas of focus for Pacira.

Pacira Pharmaceuticals excels in Q2 2024, poised for strategic growth

Pacira Pharmaceuticals (PCRX) demonstrated strong performance and strategic focus in Q2 2024, with notable achievements in product development and financial stability.
While facing challenges such as patent litigation and competitive pressures, Pacira's strengths in execution and market positioning provide a solid foundation for growth.
The company's clear guidance for 2024 and emphasis on growth priorities underscore its commitment to innovation and market leadership.
By capitalizing on opportunities in product expansion, market dynamics, and strategic partnerships, Pacira is poised for continued success and growth in the healthcare sector.

Pacira Pharmaceuticals (PCRX) reports robust Q3 performance and eyes gene therapy growth

Pacira Pharmaceuticals (PCRX) delivered a strong performance in Q3 2024, driven by increased EXPAREL sales and strategic initiatives. While facing challenges in legal battles and operational areas, the company remains focused on growth opportunities and maintaining a competitive edge in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

-- EXPAREL average daily sales return to year-over-year growth for month of June 2020 -- -- EXPAREL average daily sales return to year-over-year growth for month of June 2020 --

Pacira BioSciences Reports Preliminary Total Revenue of $75.5 Million for Second Quarter of 2020

As of late, it has definitely been a great time to be an investor of Pacira BioSciences

Will Pacira BioSciences Continue to Surge Higher?

Pacira (PCRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Pacira (PCRX) Hits 52-Week High, Can the Run Continue?

-- Orthopedic co-promotion agreement to conclude in January 2021 --    -- Significantly improves Pacira economics related to EXPAREL --

Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes

Thanks to a recent FDA decision, its best-selling product, Exparel, will go at least a little longer without facing competition from Heron Therapeutics' HTX-011.

Why Pacira BioSciences Is Soaring Today

PARSIPPANY, N.J., June  16, 2020  (GLOBE NEWSWIRE) --  Pacira BioSciences, Inc.  (NASDAQ: PCRX) today announced that it will present at the 2020 BMO Prescriptions for Success Healthcare Conference at 10:00 AM ET on Tuesday, June 23, 2020. Live audio of the  virtual event can be accessed by visiting the “Events” page of the company’s website at  investor.pacira.com . A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the 2020 BMO Prescriptions for Success Healthcare Conference

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Why Is Pacira (PCRX) Up 14.6% Since Last Earnings Report?

Zoetis

PCRX vs. ZTS: Which Stock Is the Better Value Option?

PCRX vs. ZTS: Which Stock Should Value Investors Buy Now?

Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q1 2020 Results - Earnings Call Transcript

Pacira (PCRX) beats on both earnings and revenues in the first quarter of 2020. The company temporarily suspends 2020 guidance in the wake of the COVID-19 pandemic.

Pacira's (PCRX) Q1 Earnings Top Estimates, Revenues Rise Y/Y

Pacira (PCRX) delivered earnings and revenue surprises of 65.62% and 4.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Q1 Earnings and Revenues Top Estimates

-- Veteran Industry Executive and Anesthesiologist Brings Significant Clinical and Commercial Experience in Pain Management --   PARSIPPANY, N.J., May  04, 2020  (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announces the appointment of Donald C. Manning, M.D., Ph.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Manning, who brings more than 20 years of experience in biopharmaceutical executive leadership, was most recently, Chief Medical Officer at Adynxx, Inc., a development company focused on advancing disease-modifying products for the treatment of pain management and inflammation. In his new position, Dr. Manning will report directly to David Stack, chairman and chief executive officer of Pacira BioSciences. 

Pacira BioSciences Appoints Donald C. Manning, M.D.

Catalent

PCRX vs. CTLT: Which Stock Is the Better Value Option?

PCRX or CTLT: Which Is the Better Value Stock Right Now?

Pacira (PCRX) Down 37.2% Since Last Earnings Report: Can It Rebound?

Pacira BioSciences (PCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why You Shouldn't Bet Against Pacira BioSciences (PCRX) Stock

PCRX or ZTS: Which Is the Better Value Stock Right Now?

Coca-Cola

Sempra Energy

Turning Point Brands

UnitedHealth Group

The period of a typical bear market has a propensity to be pretty lengthy. On average, bear market for the Dow and the S&P 500 lasts 206 and 146 trading days, respectively.

5 Best Stocks to Buy in a Coronavirus-Led Bear Market

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Pacira (PCRX)

Why Pacira (PCRX) Could Be an Impressive Growth Stock

Computer Programs and Systems

Mattel

Performance Food Group

Amid the doom and gloom, we have cherry picked four stocks that possess potential to perform well in the long run.

Coronavirus Triggers Rate Cut: Stocks That Can Defy Market Fall

Pacira BioSciences: Targeting Sales >$1bn By 2025 Despite New Competitive Threat

CNA Financial

Electromed

Regeneron Pharmaceuticals

Top Ranked Momentum Stocks to Buy for February 21st

Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line

Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q4 2019 Results - Earnings Call Transcript

Fortinet

Mitek Systems

Count on these top-ranked stocks that are likely to beat earnings estimates in their next releases.

News for Pacira Pharmaceuticals Stock (PCRX)